Salt AI
Category: AI in Healthcare
A contextual AI platform and collaborative operating system for life sciences that connects specialized models and datasets into interpretable, auditable AI workflows Salt AI was founded in 2023. The company is led by Aber Whitcomb. Based in Los Angeles, USA. Team size: 20. Total funding raised: $10M. Latest round: Seed. Key investors include Morpheus Ventures, Struck Capital, Marbruck Investments, CoreWeave.
- Founded
- 2023
- Headquarters
- Los Angeles, USA
- Team size
- 20
- Total funding
- $10M
Value proposition
To accelerate discovery and innovation in life sciences by enabling visual collaboration on AI workflows, ensuring rapid deployment, and providing a compliant, scalable, and cost-effective platform
Products and solutions
Salt AI Platform: A visual development environment with pre-built and customizable AI workflows for life sciences applications, Contextual AI system for protein design and biomarker discovery, Clinical evidence synthesis and diagnostics tools, Enterprise-grade AI infrastructure for regulated environments
Unique value
The platform's uniqueness lies in its visual-first, collaborative interface combined with a model-agnostic approach, specifically tailored to solve complex biological problems. This addresses the 'bilingual talent' gap between scientists and technologists
Target customer
Cross-functional teams in life sciences and healthcare, including scientists, technologists, and executives
Industries served
Life Sciences, Healthcare, Biotechnology, Pharmaceuticals
Technology advantage
Key advantages include a fully compliant stack that can be deployed in days, scalable GPU infrastructure for cost-effective performance, and an open ecosystem that allows teams to build AI solutions faster. The visual interface lowers the barrier to entry for non-technical users
How they differentiate
Salt AI offers a model-agnostic, visual-first AI development and collaboration platform specifically tailored for the life sciences sector. This focus on a specialized, user-friendly interface for a niche industry differentiates it from the more general-purpose data platforms of its competitors
Main competitors
Palantir, Databricks, Benchling
Key partnerships
Ellison Medical Institute - formal research partnership to accelerate cancer research, UCLA Bioengineering Department - computational pipelines for amino-acid sequence analysis, Hiteks - healthcare operations and clinician workflow optimization
Notable customers
Ellison Medical Institute, UCLA Bioengineering Department, Hiteks
Major milestones
Announced a formal research partnership with the Ellison Medical Institute to accelerate cancer research, Achieved 22x faster protein folding predictions in collaboration with the Ellison Medical Institute, Raised $10M Series A funding round in September 2025, Expanded leadership team with biotech and AI industry veterans in November 2025
Growth metrics
22x faster protein folding predictions achieved in collaboration with Ellison Medical Institute; Implementation time cut to weeks for drug discovery workflows
Market positioning
Salt AI is positioned as a leader in contextual AI for enterprise applications within the life sciences and health tech industries, focusing on solving complex biology problems
Geographic focus
North America, primarily United States
Patents and IP
Information on patents or specific IP is not publicly available at this time
About Aber Whitcomb
Co-Founder and CTO of MySpace, Co-Founder and CTO of Jam City
Official website: https://www.salt.ai/